Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study

#2102

Introduction: TGR0 >4%/month was associated with shorter progression-free survival (PFS) in patients (pts) treated with lanreotide in the CLARINET study. Impact of TGR0 in pts treated with other systemic therapies (ST) and with Ki67>10% is unknown.

Aim(s): To investigate correlation between TGR0 and PFS in pts with neuroendocrine tumours (NETs).

Materials and methods: Patients with advanced grade (G) 1 or 2 NETs from the pancreas (P) or small bowel (SB) starting ST or watch and wait (WW) were eligible. Pre-treatment imaging was retrospectively reviewed to calculate TGR0. Influence of TGR0 on progression-free survival (PFS) was assessed by uni/multivariable Cox Regression analyses.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Crona J

Authors: Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, TGR, RECIST, Neuroendocrine Tumor,